Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma

被引：0
|
作者：
Zhen Jin
Rufang Xiang
Kai Qing
Dan Li
Zhao Liu
Xiaoyang Li
Hongming Zhu
Yunxiang Zhang
Lining Wang
Kai Xue
Han Liu
Zizhen Xu
Yingxiao Wang
Junmin Li
机构：
[1] Shanghai Jiao Tong University,Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital affiliated to School of Medicine
[2] Shanghai Jiao Tong University,Department of General Practice, Ruijin Hospital affiliated to School of Medicine
[3] Shanghai Jiao Tong University,Faculty of Medical Laboratory Science, Ruijin Hospital, School of Medicine
[4] University of California San Diego,Department of Bioengineering & Institute of Engineering in Medicine
来源：
Cellular Oncology | 2023年 / 46卷
关键词：
CAR-T cell resistance; Diffuse large B-cell lymphoma; Lenalidomide; Anti-tumor immunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1143 / 1157
页数：14
相关论文
共 50 条
  • [21] Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
    Koksal, Hakan
    Dillard, Pierre
    Josefsson, Sarah E.
    Maggadottir, Solrun Melkorka
    Pollmann, Sylvie
    Fane, Anne
    Blaker, Yngvild Nuvin
    Beiske, Klaus
    Huse, Kanutte
    Kolstad, Arne
    Holte, Harald
    Kvalheim, Gunnar
    Smeland, Erlend B.
    Myklebust, June H.
    Inderberg, Else Marit
    Walchli, Sebastien
    BLOOD ADVANCES, 2019, 3 (08) : 1230 - 1243
  • [22] CAR-T THERAPY IN PATIENTS WITH LARGE B-CELL DIFFUSE LYMPHOMA: EXPERIENCE OF A CENTER
    Martin Lopez, A. A.
    Lopez Corral, L.
    Perez Lopez, E.
    Prieto Garcia, L.
    Cabero Martinez, A.
    Garcia Blazquez, M.
    Lopez Parra, M.
    Alana Garcia, M.
    Albala Martinez, N.
    Tamayo Alonso, P.
    Diaz Gonzalez, L.
    Arias Rodriguez, P.
    Blanco Munez, O.
    Esteban Velasco, C.
    Yeguas Bermejo, A.
    Martin Martin, L.
    Orfao, A.
    Gutierrez Gutierrez, N.
    Caballero Barrigon, D.
    Martin Garcia-Sancho, A.
    HAEMATOLOGICA, 2021, 106 (10) : 56 - 57
  • [23] Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
    Sim, Austin J.
    Jain, Michael D.
    Figura, Nicholas B.
    Chavez, Julio C.
    Shah, Bijal D.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Krivenko, Gabriel
    Davila, Marco L.
    Liu, Hien D.
    Falchook, Aaron D.
    Dahiya, Saurabh
    Rapoport, Aaron P.
    Kim, Sungjune
    Locke, Frederick L.
    Robinson, Timothy J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (05): : 1012 - 1021
  • [24] ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Sen, P.
    Saadeh, B.
    Loh, E.
    VALUE IN HEALTH, 2019, 22 : S440 - S441
  • [25] Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
    Hashmi, Hamza
    Mirza, Abu-Sayeef
    Darwin, Alicia
    Logothetis, Constantine
    Garcia, Franco
    Kommalapati, Anuhya
    Mhaskar, Rahul S.
    Bachmeier, Christina
    Chavez, Julio C.
    Shah, Bijal
    Pinilla-Ibarz, Javier
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco L.
    Locke, Frederick L.
    Nishihori, Taiga
    Jain, Michael D.
    BLOOD ADVANCES, 2020, 4 (17) : 4086 - 4090
  • [26] CAR T-cell therapy in refractory large B-cell lymphoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (01): : E19 - E19
  • [27] A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off
    Leroy, Marie
    Deramoudt, Laure
    Pinturaud, Marine
    Demaret, Julie
    Alidjinou, Enagnon Kazali
    Nudel, Morgane
    Cavalieri, Doriane
    Chahla, Wadih Abou
    Odou, Pascal
    Morschhauser, Franck
    Yakoub-Agha, Ibrahim
    Simon, Nicolas
    Beauvais, David
    LEUKEMIA & LYMPHOMA, 2024, 65 (06) : 868 - 871
  • [28] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
  • [29] T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
    Wang, Jiachen
    Shen, Kefeng
    Mu, Wei
    Li, Weigang
    Zhang, Meilan
    Zhang, Wei
    Li, Zhe
    Ge, Tong
    Zhu, Zhoujie
    Zhang, Shangkun
    Chen, Caixia
    Xing, Shugang
    Zhu, Li
    Chen, Liting
    Wang, Na
    Huang, Liang
    Li, Dengju
    Xiao, Min
    Zhou, Jianfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study
    Tomas, Ana Alarcon
    Fein, Joshua A.
    Fried, Shalev
    Fingrut, Warren
    Anagnostou, Theodora
    Alperovich, Anna
    Shah, Nishi
    Fraint, Ellen
    Lin, Richard J.
    Scordo, Michael
    Afuye, Aishat Olaide
    Batlevi, Connie Lee
    Besser, Michal
    Dahi, Parastoo B.
    Danylesko, Ivetta
    Giralt, Sergio
    Imber, Brandon S.
    Jacobi, Elad
    Nagler, Arnon
    Palomba, M. Lia
    Salles, Gilles
    Sauter, Craig S.
    Shah, Gunjan L.
    Shem-Tov, Noga
    Shimoni, Avichai
    Yahalom, Joachim
    Yerushalmi, Ronit
    Avigdor, Abraham
    Perales, Miguel-Angel
    Shouval, Roni
    BLOOD, 2021, 138
12345